Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (211-220 of 383) with videos related to

Pageof 39
Sort By:
Data in Brief|September 24, 2021
Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning periodHanne Lefrère, Giuseppe Floris, Marjanka K Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?Leen De Maeyer, Erik Van Limbergen, Katelijne De Nys, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2021
Breast cancer diagnosed in the post-weaning period is indicative for a poor outcomeHanne Lefrère, Giuseppe Floris, Marjanka K Schmidt, et al.
Oncotarget|September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trialAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal MassesAdriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, et al.
Breast Cancer Research and Treatment|September 13, 2020
Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomesFrederik Deman, Kevin Punie, Annouschka Laenen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancerAntonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Relationship between age and axillary lymph node involvement in women with breast cancerHans Wildiers, Ben Van Calster, Lonneke V van de Poll-Franse, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Pageof 39

Showing results (211-220 of 383) with videos related to

Sort By:
Pageof 39
Data in Brief|September 24, 2021
Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning periodHanne Lefrère, Giuseppe Floris, Marjanka K Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?Leen De Maeyer, Erik Van Limbergen, Katelijne De Nys, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2021
Breast cancer diagnosed in the post-weaning period is indicative for a poor outcomeHanne Lefrère, Giuseppe Floris, Marjanka K Schmidt, et al.
Oncotarget|September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trialAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal MassesAdriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, et al.
Breast Cancer Research and Treatment|September 13, 2020
Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomesFrederik Deman, Kevin Punie, Annouschka Laenen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancerAntonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Relationship between age and axillary lymph node involvement in women with breast cancerHans Wildiers, Ben Van Calster, Lonneke V van de Poll-Franse, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Pageof 39